- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01677143
Pre-emptive Local Anaesthesia in Gynecological Laparoscopy
Přehled studie
Detailní popis
The study design is prospective, randomized, and double-blinded with parallel assignments. It will compare pre-emptive incisional injection of bupivacaine, 5 mg/ml, with a placebo injection (saline). The clinically relevant comparison should probably be between injection of local anaesthetics and no injection at all. However a study design like that would make blinding impossible and probably not acceptable as a research design for a study which aims to be published.
The aim of the study is to test if pre-emptive injection of long-lasting, local anaesthetics reduces post-operative pain. As local anaesthetics are already implemented in our routine, the hypothesis is that it has a positive effect by reducing postoperative pain. The null hypothesis is that there is no difference between local anaesthetics and placebo.
The recruitment of patients will be from our daily surgery, and consecutive patients who are eligible for day-case, laparoscopic surgery will be asked to participate.
To have a clinically important reduction of post-operative pain a difference of 2 units on a 0-10 numerical rating scale (NRS) is chosen for the sample size calculation. A smaller difference in pain score is not considered clinically relevant in our opinion. With a power of at least 80% this gives 20 patients in total, 10 in each arm. The power calculation was done by statistician S. Johnsen at the University of Surrey. We will include 24 patients altogether to cover for any losses to follow-up. The drop-out rates in clinical trials are usually estimated at 20 %, which would give 25 patients to be included (20/ (1-0.2) = 25). This study has, however, a very short follow-up period, so the drop-out rate is expected to be smaller. Drop-outs will be recorded and accounted for.
24 participants will be randomized in blocks of 6 patients. Block randomization is chosen to avoid pooling by chance.
All procedures will be done by one surgeon. This might be a subject for criticism as one can say that the results in the study are only true for one surgeon in a particular setting. But the need for standardization is very important in studies like this, as pointed out by Wilder-Smith (Wilder-Smith, O. H. 2000).
The time of the randomization is identified as the breakage of the study drug vial. If a potential candidate is found to satisfy any exclusion criteria or withdraws the consent before the vial is opened, the patient is not randomised. The study ID number and the study drug vial will be made available for the next potential candidate.
If a potential candidate is excluded for any reason after the breakage of the vial but before the completion of the injection of the study drug, the study ID number will be coded as Protocol Violation and excluded from the statistical analyses.
The patient, nursing staff and the surgeon will all be blinded to the substance injected.
Infiltration in the primary, umbilical site will be blind, but as close to the fascia as possible. The secondary port infiltrations will be done under visual guidance from the laparoscope, in the fascia and close to the peritoneum. Bupivacaine in a concentration of 5 mg/ml will be used and 5 ml of the solution will be injected at each port site. The patients who get placebo will get 5 ml of physiologic saline injected at each port site.
The primary outcome of the study will be movement-evoked pain (MEP) 5 hours after surgery, as half-life of bupivacaine is 4-6 hours. Movement-evoked pain is the most important outcome measure, because the goal is to get the patient back to normal, daily activities as soon as possible. Trials measuring both movement evoked pain and pain at rest (PAR) suggests that MEP is much more intense than PAR postoperative (Srikandarajah et al, 2011). Pain will be measured on a 10 cm long Numerical Rating Scale (NRS) where 0 cm is no pain and 10 cm is severe pain. NRS is validated as a good tool for pain measurement at different ages and education levels (Gagliese et al, 2005).
Secondary outcome measures will be pain at rest at 2 and 5 hours postoperative, and use of rescue analgesics. Pain at rest must, of course, be recorded before movement evoked pain.
The pain scoring will be done by the patient with help from the nurses at the ward at 2 and 5 hours postoperative, and both will be blinded to which arm the patient is in.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 4
Kontakty a umístění
Studijní místa
-
-
-
Stavanger, Norsko, 4068
- Stavanger University Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Women ≥18 years of age
- Planned day-case laparoscopic surgery
- Signed Written Informed Consent
Exclusion Criteria:
- ASA score 3-6
- Chronic pain/ Regular use of analgesics
- Inability to understand Norwegian language
- Drug or alcohol abuse
- Inability to understand or sign the Written Informed Consent form
Studijní plán
Jak je studie koncipována?
Detaily designu
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: bupivacaine
Injection of 5 ml bupivacaine, 5mg/ml in each port site.
|
5 ml in trocar area
Ostatní jména:
|
|
Komparátor placeba: Placebo
Injection of 5 ml saline in each port site.
|
5 ml in trocar area
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Postoperative movement-evoked pain
Časové okno: 5 hours postoperative
|
The primary outcome of the study will be movement-evoked pain (MEP) 5 hours after surgery, as half-life of bupivacaine is 4-6 hours.
Movement-evoked pain is the most important outcome measure, because the goal is to get the patient back to normal, daily activities as soon as possible.
|
5 hours postoperative
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pain at rest
Časové okno: 2 and 5 hours postoperative
|
Secondary outcome measures will be pain at rest at 2 and 5 hours postoperative.
|
2 and 5 hours postoperative
|
|
Rescue analgetics
Časové okno: 5 hours postoperative
|
Use of rescue analgesics postoperative.
|
5 hours postoperative
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Caroline Ravndal, MD, Helse Stavanger HF
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- SUS2012CMR01
- 2012-002356-16 (Číslo EudraCT)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Bolest, pooperační
-
Liu JiuhongDokončenoRebound Pain | Lipozomální bupivakainČína
-
University of VirginiaZatím nenabírámeArtroplastika ramene | Interscalene Block | Rebound PainSpojené státy
-
Karaman Training and Research HospitalDokončeno
-
Ajou University School of MedicineNábor
-
Beijing Sport UniversityZatím nenabírámePatellofemoral Pain, PFP
-
Beijing Sport UniversityZatím nenabíráme
-
Istanbul University - CerrahpasaNáborPatellofemoral Pain, PFPTurecko (Türkiye)
-
Pamukkale UniversityZatím nenabírámePatellofemoral Pain, PFPTurecko (Türkiye)
-
Beijing Sport UniversityDokončenoPatellofemoral Pain, PFPČína
-
The First Affiliated Hospital of Xiamen UniversityNáborRebound Pain | Artroskopická operace kolena | OliceridinČína
Klinické studie na Bupivacaine 5mg/ml
-
EMSStaženo
-
Beijing Anzhen HospitalZatím nenabíráme
-
Zealand University HospitalDokončeno
-
Sun Yat-sen UniversityZatím nenabírámeKarcinom, nemalobuněčné plíceČína
-
Guangdong Hengqin Novagains Biopharmaceutical Co...Xiangbei Welman Pharmaceutical Co., Ltd; Guangzhou Xin-Chuangyi Biopharmaceutical...Zápis na pozvánkuHyperurikémie s dnou nebo bez níČína
-
Medicines for Malaria VentureGlaxoSmithKline; ICON plc; QIMR Berghofer Medical Research Institute; Southern... a další spolupracovníciDokončenoPatologické procesy | Infekce | Syndrom systémové zánětlivé odpovědi | Zánět | Nemoci přenášené vektorem | Parazitární onemocnění | Protozoální infekce | Malárie | Parazitémie | Malárie, Falciparum | Antiinfekční látky | AntimalarikaAustrálie
-
Shanghai Zhimeng Biopharma, Inc.Zatím nenabíráme
-
University of AbujaWashington University School of Medicine; Northwestern University; Fogarty International...Aktivní, ne náborDiabetes mellitus 2. typu (T2DM)Nigérie
-
AmtixBio Co., Ltd.Novotech (Australia) Pty LimitedDokončeno
-
Novo Nordisk A/SDokončenoDiabetes mellitus, typ 2Německo